Sanofi-Aventis shares dive after FDA panel rejects weight-loss drug Accomplia - PARIS (AP) - Shares of French pharmaceutical company Sanofi-Aventis plunged Thursday as investors reacted to U.S. federal health advisers’ rejection of the company’s Accomplia weight-loss drug. The Food and Drug administration’s advisory panel turned down the drug, also known as rimonabant and Ziumlti, after hearing testimony that it increases the risk of suicidal thoughts, even in patients without a history of depression. Sanofi-Aventis failed to show the drug is safe, the FDA panel said Wednesday.
International Press Release Publishing for free in 15 languages across 22 countries
Press Releases
Google-Suche:
 

Send this page to somebody

Fill in the email address of your friend to send an email with the address.
Address info
(Required)
The e-mail address to send this link to.
(Required)
Your email address.
A comment about this link.
SUBCATEGORIES
Nutrition
 
 
Pressreleases by authors
A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z